Denali Therapeutics Inc. (DNLI)

Over the past six months, several events have impacted Denali Therapeutics' stock price. The FDA approval of AVLAYAH™ for Hunter Syndrome likely had a favorable impact. Takeda ended their collaboration for DNL593, which can be perceived negatively. Fourth Quarter and Full Year 2025 Financial Results highlighted commercial launch readiness, clinical progress, a royalty deal, and a public offering. Denali completed an equity financing and announced a royalty funding agreement. As of April 2, 2026, the share price was $20.65, representing an increase of 78.02% over the price on April 7, 2025.

There is no direct information available regarding demand seasonality for Denali Therapeutics' products and services. Demand for its products would likely be driven by patient need and medical prescription rather than typical seasonal consumer patterns.

Denali Therapeutics is a biotechnology company focused on discovering and developing therapeutics to combat neurodegenerative and lysosomal storage diseases, operating within the Healthcare sector, specifically in the Biotechnology industry. The company's core business revolves around its proprietary TransportVehicle™ (TV) platform, designed to enable large therapeutic molecules to cross the blood-brain barrier (BBB) and deliver medicines to the brain and other parts of the body. Major product candidates include the LRRK2 Inhibitor Program for Parkinson's disease, the RIPK1 Inhibitor Program for peripheral inflammatory diseases, DNL310 Tividenofusp alfa (AVLAYAH™) for Hunter syndrome (MPS II), DNL126 for Sanfilippo syndrome type A (MPS IIIA), TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN), Enzyme TransportVehicle (ETV) programs, and Antibody Transport Vehicle (ATV) and OTV programs.

Denali Therapeutics is headquartered in South San Francisco, California, United States, with additional locations in Salt Lake City, Utah, and Zurich, Switzerland. The company is also pursuing international expansion, including a strategic alliance for a potential late 2026 EU launch.

Denali Therapeutics has generally maintained a positive brand reputation over the past year, primarily driven by advancements in its pipeline and strategic collaborations. The U.S. FDA approval of AVLAYAH™ for Hunter Syndrome in March 2026 is a significant positive event. Collaborations with major pharmaceutical companies like Biogen and Sanofi also underscore its potential and commitment to innovation. The company's focus on addressing neurodegenerative and lysosomal storage diseases contributes to a favorable public perception.

Denali Therapeutics' ownership is heavily influenced by institutional investors, who collectively hold over 90% of the company's stock. Major institutional shareholders include BlackRock, Inc., The Vanguard Group, Inc., Baillie Gifford & Co, Wellington Management Group LLP, UBS Asset Management AG, FMR LLC, Biogen Inc., Temasek Holdings (Private) Limited, State Street Corp, Norges Bank, Price T Rowe Associates Inc /md/, and Goldman Sachs Group Inc. Key individual and insider shareholders include Robert Nelsen, Ryan Watts, and Alexander Schuth.